A male infant with COVID-19 in the context of ARPC1B combined deficiency

Jaramillo, Lina Maria Castano; Nakashimada, Marco Yamazaki; Mendoza, Selma Cecilia Scheffler; Ogando, Juan Carlos Bustamante; Espinosa, Sara; Reyes, Saúl

doi:10.22541/au.159170773.34049082

2020

DOI: 10.22541/au.159170773.34049082

|View full text |Cite

Preprint

A male infant with COVID-19 in the context of ARPC1B combined deficiency

Lina Maria Castano Jaramillo

Marco Yamazaki Nakashimada²,

Selma Cecilia Scheffler Mendoza

et al.

Abstract: The current pandemic of the novel coronavirus SARS-CoV-2 infection has affected over 6 million humans around the planet. The clinical manifestations of Coronavirus disease 2019 (COVID-19) are diverse, ranging from asymptomatic or mild flu-like symptoms to atypical pneumonia, severe respiratory distress syndrome, systemic inflammation, immune dysregulation and dyscoagulation.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 6 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

COVID-19 in the Context of Inborn Errors of Immunity: a Case Series of 31 Patients from Mexico

Castaño-Jaramillo¹,

Yamazaki‐Nakashimada²,

O’Farrill-Romanillos

et al. 2021

J Clin Immunol

126

View full text Add to dashboard Cite

Highlights1. What is already known about this topic? SARS-CoV-2 causes asymptomatic or mild infection in about 80% of humans, while an excessive immune response has killed millions. Differential susceptibility and risk factors became a concern early in the pandemic. Several monogenic defects that involve innate viral sensors or affect interferon response pathways, as well as autoantibodies against type 1 interferons, have been identified in 14% of patients with life-threatening COVID-19. The impact of the novel betacoronavirus infection in patients with known inborn errors of immunity is less clear. Case series and reports from different countries have suggested a minor impact or even a potential protective effect of the IEI for some patients.2. What does this article add to our knowledge? We describe findings and outcomes of COVID-19 in 31 pediatric and adult patients with known IEI from Mexico, 84% of whom survived. Pediatric patients had a higher hospitalization rate. Inpatient mortality was 40%, and ICU mortality was 63%. Six patients died of secondary bacterial infection or uncontrolled systemic inflammation, but not from overwhelming viral infection. One patient with an autoinflammatory disorder under treatment with anakinra had a catastrophic clinical course. Eighty percent of patients received IVIG as part of their treatment for acute SARS-CoV-2 infection.3. How does this study impact current management guidelines? We recommend continued and/or high-dose IVIG in patients with known IEI seeking care for COVID-19. Patients with autoinflammatory disorders, especially those with inflammasome dysregulation, should probably take extreme measures to prevent exposure, while doctors taking care of SARS-CoV-2 infected patients with immune deficiencies must do everything they can to prevent secondary bacterial infections. The high survival of patients with COVID-19 in the context of inborn errors of immunity worldwide (over 80%) might be the result of patientphysician awareness and special care.

show abstract

COVID-19 in the Context of Inborn Errors of Immunity: a Case Series of 31 Patients from Mexico

Castaño-Jaramillo¹,

Yamazaki‐Nakashimada²,

O’Farrill-Romanillos

et al. 2021

J Clin Immunol

126

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

A male infant with COVID-19 in the context of ARPC1B combined deficiency

Cited by 1 publication

References 6 publications

COVID-19 in the Context of Inborn Errors of Immunity: a Case Series of 31 Patients from Mexico

COVID-19 in the Context of Inborn Errors of Immunity: a Case Series of 31 Patients from Mexico

Contact Info

Product

Resources

About